MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS

Abstract

MiR-143-3p may suppress tumorigenesis in PDAC by targeting KRAS. This might provide a theoretical basis for miR-143-3p in treatment of pancreatic cancer.